Surgical Aortic Valve Replacement in Cancer Survivors with Severe Symptomatic Aortic Valve Disease: A Retrospective Single-Center Observational Study
Cancers · 12.10.2025 · 17 (20) · 3301
DOI: 10.3390/cancers17203301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.10.2025. Verfasst von Ivo Deblier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department Cardiovascular Surgery, ZNA Middelheim General Hospital, Lindendreef 1, 2020 Antwerp, Belgium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Cancer survivors can develop heart conditions such as aortic valve disease because of age and other shared risk factors. If this valve condition becomes symptomatic, the prognosis is poor if the valve is not replaced. Surgical aortic valve replacement (SAVR) is one mode of treatment.
Methods
Of 2500 consecutive patients who underwent SAVR with a biological valve, 388 patients were cancer survivors. They were compared for preoperative characteristics, operative parameters, postoperative adverse events, need for resources, and long-term survival. For the latter, the six most common tumors (prostate, breast, colorectal, bladder, pulmonary, and hematologic) and the effect of the interval between cancer treatment and cardiac surgery were scrutinized.
Results
Cancer increased significantly over time. Pulmonary and kidney disease differed between the groups, but cardiac comorbid conditions did not. Operative parameters, early adverse events, and need for resources did not differ. Median survival time was significantly reduced in cancer survivors: 104 (97–112) versus 119 (116–122) months, and this was driven by an interval of less than 5 years and prior lung cancer. Prior cancer was the least important of ten predictors for long-term mortality.
Conclusions
The outcome of cancer survivors after SAVR is acceptable. For patients with pulmonary cancer, the outcome is poor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department Cardiovascular Surgery, ZNA Middelheim General Hospital, Lindendreef 1, 2020 Antwerp, Belgium.
- Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
ORCID-Profile: Ivo Deblier, Ruben Deblier, Wilhelm Mistiaen
Zitieren
APA
Deblier, I., Deblier, R., & Mistiaen, W. (2025). Surgical Aortic Valve Replacement in Cancer Survivors with Severe Symptomatic Aortic Valve Disease: A Retrospective Single-Center Observational Study. Cancers, 17(20), 3301. https://doi.org/10.3390/cancers17203301
Vancouver
Deblier I, Deblier R, Mistiaen W. Surgical Aortic Valve Replacement in Cancer Survivors with Severe Symptomatic Aortic Valve Disease: A Retrospective Single-Center Observational Study. Cancers. 2025;17(20):3301. doi:10.3390/cancers17203301
BibTeX
@article{Deblier2025,
author = {Deblier, Ivo and Deblier, Ruben and Mistiaen, Wilhelm},
title = {Surgical Aortic Valve Replacement in Cancer Survivors with Severe Symptomatic Aortic Valve Disease: A Retrospective Single-Center Observational Study},
journal = {Cancers},
year = {2025},
volume = {17},
number = {20},
pages = {3301},
doi = {10.3390/cancers17203301}
}
EUVIMED